Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dementias Platform UK is excited to announce its fantastic line-up of academic and industry keynote speakers and sessions for the Translation 2023 conference.

Panellists at DPUK's five-year celebration event
Panel at a DPUK event

View the Translation 2023 Conference Programme

More details regarding session speakers will be announced in due course.

We are extremely pleased to introduce our confirmed academic and industry keynote speakers Professor Sir Simon Lovestone, Professor Jeff Cummings and Dame Kate Bingham. 

Professor Sir Simon Lovestone

Professor Sir Simon LovestoneProfessor Sir Simon Lovestone

Simon joined Janssen as Neuroscience DAS leader for neurodegenerative disorders in 2018 and is now Global Lead for Neuroscience Discovery and Translation.

Prior to moving to industry, he was Professor of Translational Neuroscience at Oxford University where he founded and led the ARUK Dementia Drug Discovery Institute with Chas Bountra, and before that was at King’s College London where he led the Biomedical Research Centre for Mental Health. His research interests are in the mechanisms of Alzheimer’s Disease and in the search for biomarkers and building on these, in drug discovery and experimental medicine. He studied Microbiology at Sheffield University, Medicine at Southampton University and his PhD was from the University of London for research on role of GSK3 in phosphorylation of tau.

He was knighted for services to Neuroscience research in 2017.

Professor Jeff Cummings

Professor Jeff CummingsProfessor Jeff CummingsJeffrey Cummings, MD, ScD, is the Joy Chambers-Grundy Professor of Brain Science, Director of the Chambers-Gundy Center for Transformative Neuroscience, Co-Director of the Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV). 

Dr. Cummings is globally recognised for his contributions to Alzheimer’s research, drug development, and clinical trials.  He has been recognised for his research and leadership contributions in the field of Alzheimer’s disease through many awards including the Ronald and Nancy Reagan Research Award of the national Alzheimer’s Association (2008), Lifetime Achievement Award of the Society for Behavioral and Cognitive Neurology (2017), Distinguished Scientist Award of the American Association of Geriatric Psychiatry (2010), Bengt Winblad Lifetime Achievement Award from the national Alzheimer’s Association (2019), and the Alzheimer’s Drug Discovery Foundation’s Melvin R. Goodes Prize. He was featured in the Gentleman’s Quarterly (June 2009) as a “Rock Star of Science™.” 

Dr. Cummings completed Neurology residency and a Fellowship in Behavioural Neurology at Boston University, followed by a Research Fellowship in Neuropathology and Neuropsychiatry at the National Hospital for Nervous Diseases, Queen Square, London. Dr. Cummings was formerly Director of the Mary S. Easton Center for Alzheimer’s Disease Research at UCLA, and Director of the Cleveland Clinic Lou Ruvo Center for Brain Health.

Dr. Cummings’ interests embrace clinical trials, developing new therapies for brain diseases, and the interface of neuroscience and society.  He has authored or edited 43 books and published over 800 peer-reviewed papers. 

 

DAME KATE BINGHAM 

Dame Kate BinghamDame Kate BinghamIn her 30 years at SV Health Investors, Kate’s biotech investments have resulted in the launch of eight drugs for the treatment of patients with inflammatory and autoimmune disease and cancer.

Kate co-leads SV’s biotech franchise which has a long history of building high value, successful new companies developing transformational new medicines and bringing drugs from discovery to market. Kate’s investments, many of which are examples of SV’s company creation approach to biotech investing, include a wide range of drug discovery and development companies focused on different clinical areas in companies in the  UK, EU and US.

In 2021 Kate was awarded a DBE in the Queen’s Birthday Honours for her services as Chair of the UK Vaccine Taskforce, where she led a team of world-class experts with the shared purposed of finding and manufacturing COVID-19 vaccines.